Vial
Vial, a CRO, revolutionizes clinical trials for biotech sponsors, offering faster, cost-effective results via tech integration.
Founded
2020Vial, a CRO, revolutionizes clinical trials for biotech sponsors, offering faster, cost-effective results via tech integration.
Vial, founded as a contract research organization (CRO), is dedicated to transforming clinical trials for biotech sponsors. The company's core mission is to enable scientists to discover groundbreaking therapeutics that improve human health and happiness. Vial offers a comprehensive suite of services, including trial onboarding, patient enrollment, site communication, and data collection, all integrated into a modern technology platform. The company focuses on various therapeutic areas such as oncology, dermatology, ophthalmology, gastroenterology, CNS, cardiology, respiratory, and rare diseases.
Notable figures affiliated with Vial include experienced professionals in clinical operations and technology integration. The company has attracted significant investment from prominent venture capital firms. Key achievements include the successful execution of numerous clinical trials that have accelerated the development of new therapies while reducing costs. Vial's innovative approach has had a substantial impact on the biotech industry, making clinical trials more efficient and accessible.
Companies similar to Vial include Clinical Research IO, Novotech, Curavit Clinical Research and TrialSpark.
Vial was founded in 2020.
Vial's headquarters is located in San Francisco, CA, US.
Vial's most recent funding round was for $34M (USD) in November 2022.
As of Nov 30, 2022, Vial has disclosed funding of $101M (USD). Undisclosed round amounts are excluded.
Vial has 187 employees as of Feb 4, 2024.
trialspark.com
